The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM
The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM
Which MIC do we use? Carbapenem MICs against KPC producers vary significantly between microdilution, Etest, agar dilution, disk diffusion, and automated assays Pournaras et al 2010 J Clin Microbiol 48:2601-2604 Bratu et al 2005 Antimicrob Agents Chemother 49:776-778 Antimicrob Agents Chemother 49:3018-3020 Arch Intern Med 165:1430-1435 Samra et al. 2007 IJAA 30:525-529
KPC-producing K. pneumoniae: Carbapenem MICs (µg/ml) Isolate Method Meropenem Ertapenem 12 VITEK 2 >16 4 BD Phoenix 4 Agar Dilution 16 16 48 VITEK 2 >16
- Page 1: The Evolving Threat of ESBL, AmpC,
- Page 4 and 5: Normal Gram-negative
- Page 6 and 7: ß-lactamases O CH 2 C NH O N S CH
- Page 8 and 9: Old Plasmid-Encoded ß-lactamases T
- Page 10 and 11: 3 rd Generation Cephalosporins Cefo
- Page 12 and 13: Evolution of ESBLs TEM-3, 4 ......
- Page 14 and 15: ESBL-producing Organisms Most Commo
- Page 16 and 17: CLSI 2010 (M100-S20) • If laborat
- Page 18 and 19: 2010 Breakpoints: Are they sufficie
- Page 20: Inoculum Effect: In Vitro Artifact?
- Page 23 and 24: -lactams Still Active Carbapenems C
- Page 25 and 26: AmpC-mediated Resistance Resistant
- Page 27 and 28: Plasmid-mediated AmpCs • Klebsiel
- Page 29 and 30: Clinical Significance of AmpC for K
- Page 31 and 32: Klebsiella pneumoniae 225 Resistant
- Page 34 and 35: Carbapenemases Class A (KPC, GES, S
- Page 36 and 37: Miami KPC Outbreak • Admission fi
- Page 41: Thanks for your attention!
<strong>KPC</strong>-producing K. pneumoniae:<br />
Carbapenem MICs (µg/ml)<br />
Isolate Method Meropenem Ertapenem<br />
12 VITEK 2 >16 4<br />
BD Phoenix 4<br />
Agar Dilution 16 16<br />
48 VITEK 2 >16
Change language